CITIUS PHARMAC (Germany) Top Insiders
47N Stock | EUR 3.29 0.00 0.00% |
Examination of CITIUS PHARMAC's management performance can provide insight into the company performance.
CITIUS |
Symbol | 47N |
Name | CITIUS PHARMAC DL |
Type | Stock |
Country | Germany |
Exchange | F |
Information on CITIUS PHARMAC DL Leadership is currently not available.
If you believe this information is not accurate please let us know and we will check it out. Check all delisted instruments across multiple markets.Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Thematic Opportunities
Explore Investment Opportunities
CITIUS PHARMAC Management Team Effectiveness
The company has return on total asset (ROA) of (0.1624) % which means that it has lost $0.1624 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2848) %, meaning that it generated substantial loss on money invested by shareholders. CITIUS PHARMAC's management efficiency ratios could be used to measure how well CITIUS PHARMAC manages its routine affairs as well as how well it operates its assets and liabilities.CITIUS PHARMAC Workforce Comparison
CITIUS PHARMAC DL is number one stock in number of employees category among its peers. The total workforce of Biotechnology industry is presently estimated at about 55,102. CITIUS PHARMAC adds roughly 21.0 in number of employees claiming only tiny portion of stocks in Biotechnology industry.
CITIUS PHARMAC DL Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. CITIUS PHARMAC DL Price Series Summation is a cross summation of CITIUS PHARMAC price series and its benchmark/peer.
About CITIUS PHARMAC Management Performance
The success or failure of an entity such as CITIUS PHARMAC DL often depends on how effective the management is. CITIUS PHARMAC management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of CITIUS management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the CITIUS management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products targeting medical needs with a focus on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. CITIUS PHARMAC operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 10 people.
Complementary Tools for CITIUS Stock analysis
When running CITIUS PHARMAC's price analysis, check to measure CITIUS PHARMAC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CITIUS PHARMAC is operating at the current time. Most of CITIUS PHARMAC's value examination focuses on studying past and present price action to predict the probability of CITIUS PHARMAC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CITIUS PHARMAC's price. Additionally, you may evaluate how the addition of CITIUS PHARMAC to your portfolios can decrease your overall portfolio volatility.
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |